General description

A cell-permeable hydroxyamide-based SAHA analog that potently inhibits histone deacetylase (HDAC) activity (IC₅₀ = 100 nM). Shown to induce histone acetylation and p21 transcription with concomitent inhibition of cell cycle progression in human fibrosarcoma HT1080 cells. Reported to be more potent than SAHA in inhibiting tumor growth in a murine xenograph model in vivo.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Kim, D.H., et al. 2007. Biochem. Biophys. Res. Commun.356, 233.

Packaging

Packaged under inert gas

10 mg in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Warning

Toxicity: Irritant (B)